Bendamustine/Rituximab as Induction Therapy in MCL

Video

<br /> Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, The University of British Columbia, discusses a retrospective analysis evaluating bendamustine and rituximab as induction therapy in both transplant eligible and ineligible patients with mantle cell lymphoma.&nbsp;<br /> &nbsp;

Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, The University of British Columbia, discusses a retrospective analysis evaluating bendamustine and rituximab (Rituxan) as induction therapy in both transplant eligible and ineligible patients with mantle cell lymphoma (MCL).

Related Videos
Related Content